Skip to main content

Benitec Biopharma Inc.

corporate_fare Company Profile

Benitec Biopharma Inc.

BNTC·NASDAQ·Life Sciences·CIK 0001808898

Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on developing new genetic medicines. The company is developing BB-301, a silence and replace-based therapeutic for Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. BB-301 is an AAV-based gene therapy designed to permanently silence the expression of the disease-causing gene to slow or halt disease progression in OPMD. Simultaneously, it aims to replace the mutant gene with a functional gene to restore function in diseased cells. This therapeutic approach, known as "silence and replace," seeks to restore normal cell and tissue physiology and improve treatment outcomes for OPMD patients. BB-301 has received Orphan Drug Designation and Fast Track Designation in the United States, and Orphan Drug Designation in the European Union. Benitec's proprietary technology platform is called DNA-directed RNA interference (ddRNAi) and "silence and replace." ddRNAi is designed to achieve permanent silencing of disease-causing genes by combining RNA interference (RNAi) with viral delivery agents, specifically viral vectors, typically used in gene therapy. The company will require additional financing to advance its product candidates.

Benitec Biopharma Inc. (NASDAQ:BNTC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for BNTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for BNTC spans 8-K, 10-K, 10-Q, S-3.

Recent high-impact activity:

  • Benitec's BB-301 Hits 100% Response Rate; High Dose Beats Low Dose at Month 3
  • BB-301 Hits 100% Response Rate Across Both Dose Cohorts in OPMD Study
  • FDA Feedback on BB-301 Pivotal Design Adds Clarity; Enrollment Still on Track for Mid-2027
  • Benitec Swaps Auditor: Baker Tilly Out, EY In
  • Benitec FY2026 10-K: $180M Cash, Material Weakness Remediated, BB-301 Pivotal Design Discussed with FDA

Financial Snapshot

Fiscal year ended June 30, 2026
Net Income
-$45.55M
Diluted EPS
-$0.98
Op. Cash Flow
-$16.52M
Free Cash Flow
-$16.62M
Operating Income
-$51.19M
Cash & Equivalents
$179.97M
Debt / Equity
0.00×
Shares Outstanding
34.42M sh
Source: 10-K · filed 2026-09-14 · accession 0001193125-26-390570

Short Interest & Short Volume

11.30 days to cover

FINRA reported short interest of 1,994,400 shares in BNTC as of the October 30, 2026 settlement, a 0.1% increase from the prior period — about 11.3 days to cover at its recent average daily volume. On November 20, 2026, 68.9% of BNTC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,994,400 shares as of October 30, 2026
Change vs prior period▲ 0.1%
Days to cover11.30 at avg daily volume of 176,530
Daily short volume (FINRA facilities)68.9% of 66,012 shares on November 20, 2026
5-day average short volume66.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for BNTC, detected from its recent SEC filings.

1 shelf registration

New $200M Universal Shelf Filed · Separate from Existing Shelf

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with B →
$8.14
52-week range · as of 2026-10-28 $8 – $16.76
Market cap
$285.88M
Volume
268.7K (1.4× avg)
3-mo avg 185.5K
Live data · 2026-11-21 12:24 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BNTC - Latest Insights

BNTC
Oct 28, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.80
Real-time Price: $8.14 info
Change: -$0.660 (-8%) info
Market Cap: $285.882M info
BNTC
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $8.80
Real-time Price: $8.14 info
Change: -$0.660 (-8%) info
Market Cap: $285.882M info
BNTC
Oct 05, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.92
Real-time Price: $8.14 info
Change: -$0.780 (-9%) info
Market Cap: $285.882M info
BNTC
Sep 24, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.64
Real-time Price: $8.14 info
Change: -$1.50 (-16%) info
Market Cap: $285.882M info
BNTC
Sep 14, 2026, 4:09 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $12.09
Real-time Price: $8.14 info
Change: -$3.95 (-33%) info
Market Cap: $285.882M info
BNTC
Sep 14, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.08
Real-time Price: $8.14 info
Change: -$3.94 (-33%) info
Market Cap: $285.882M info
BNTC
May 14, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.65
Real-time Price: $8.14 info
Change: -$3.51 (-30%) info
Market Cap: $285.882M info
BNTC
May 14, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.65
Real-time Price: $8.14 info
Change: -$3.51 (-30%) info
Market Cap: $285.882M info
BNTC
Apr 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.89
Real-time Price: $8.14 info
Change: -$4.75 (-37%) info
Market Cap: $285.882M info
BNTC
Mar 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $12.00
Real-time Price: $8.14 info
Change: -$3.86 (-32%) info
Market Cap: $285.882M info
BNTC
Feb 12, 2026, 8:09 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.65
Real-time Price: $8.14 info
Change: -$3.51 (-30%) info
Market Cap: $285.882M info
BNTC
Feb 12, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $11.65
Real-time Price: $8.14 info
Change: -$3.51 (-30%) info
Market Cap: $285.882M info
BNTC
Jan 30, 2026, 4:02 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $12.18
Real-time Price: $8.14 info
Change: -$4.04 (-33%) info
Market Cap: $285.882M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets